Danielle Pastor

Danielle M. Pastor, D.O., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology


Dr. Pastor is dedicated to identifying and developing immunotherapy-based treatment regimens for individuals with cancer through early-phase clinical studies, including first-in-human trials. Her work as an Assistant Research Physician in the  Center for Immuno-Oncology (CIO) Clinical Trials Group focuses on gastrointestinal malignancies, particularly colon and rectal cancer. She has special interest in hereditary colorectal cancer syndromes, as well as in the processes contributing to carcinogenesis in early-onset colorectal cancer and patient populations known to be at higher risk for the development of intestinal cancer.

Dr. Pastor works closely with CIO scientists and other NCI investigators with the goal of improving patient response rates, overall outcomes, and quality of life through the utilization of combinations of novel immune-stimulating agents, “standard” chemotherapy, and targeted agents.

Areas of Expertise

Therapeutic Cancer Vaccines
Solid Tumors
Gastrointestinal Malignancies
Colon And Rectal Cancer
Hereditary Colorectal Cancer Syndromes

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Clinical Trials


Selected Key Publications

Immunology of Lynch Syndrome

Pastor DM, Schlom J.
Curr Oncol Rep. 23(8): 96, 2021. [ Journal Article ]

Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report

Pastor DM, Lee-Wisdom K, Arai AE, Sirajuddin A, Rosing DR, Korchin B, Gulley JL, Bilusic M.
Front Oncol. 10: 603248, 2020. [ Journal Article ]

Sleep Dysfunction in Gastrointestinal Malignancy. In: Sleep Effect on Gastrointestinal Health & Disease: Translational Opportunities for Promoting Health and Optimizing Disease Management

Copare JL, Pastor DM, Alimi A, Johnson DA. Editors: DA Johnson, WC Orr, JC Ware.
2018. [ Book Chapter ]

Tumor necrosis factor alpha induces p53 up-regulated modulator of apoptosis expression in colorectal cancer cell lines

Pastor DM, Irby RB, Poritz LS.
Dis Colon Rectum. 53(3):: 257-63, 2010. [ Journal Article ]

Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network

Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, Stuart JM, Irby RB, Lee NH.
Mol Cancer. 9: 98, 2010. [ Journal Article ]


Bonnie L. Casey
Patient Care Coordinator (Contr.)
Cynthia Moye
Patient Care Coordinator (Contr.)
Camilo Pacheco Puentes
Physician Assistant
Lauren Skeffington, M.S.